Phase II Study of Tiragolumab and Atezolizumab Treatments in Adults with Advanced Solid Tumors Not Suitable for Surgery or Standard Therapy

What this Trial Is About

Researchers are evaluating the effects of two monoclonal antibodies, tiragolumab and atezolizumab, in patients with locally advanced or metastatic solid cancers that cannot be removed by surgery or have spread. These cancers have specific characteristics that may predict how well they respond to immune-based treatments. The study focuses on blocking immune receptors PD-L1 and TIGIT, which tumors use to avoid attack by the immune system, with the goal of reactivating the bodys ability to fight the cancer. Patients who have been screened through specific cancer programs and whose tumors fit the study criteria will join after a 21-day screening period. At the start, patients receive tiragolumab alone, followed by combined tiragolumab and atezolizumab every 21 days. Treatment continues in cycles until it is stopped, with biopsies and imaging done to monitor tumor response. Participants are divided into subgroups based on tumor mutation burden, PD-L1 expression, gene amplification, or tumor-infiltrating lymphocytes. Throughout the study, participants will have biopsies, CT scans, and samples of blood, urine, and stool collected. Follow-up visits and calls will continue after treatment ends to track disease progression and survival for up to 12 months or until death. Researchers will assess progression-free survival at 6 months as the primary outcome, along with tumor response, overall survival, quality of life, and safety measures throughout the study period.

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients